1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
3
Active Trials
200 recruiting
2
Rare Diseases
across 3 areas
0
News (30d)
Quiet
Shanghai Zhimeng Biopharma, Inc. is a company with 1 orphan drug designation across 2 rare diseases. Active clinical trials in 3 indications. 2 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| amyotrophic lateral sclerosis | N-(2-(4-Fluorophenyl)-5,7-dimethyl-1,2,3,4-tetrahydro isoquinolin-6-yl)-2-(1-methylcyclopropyl) acetamide | Des.TrialAppr. |
| epilepsy | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
13
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
2
affecting portfolio
0% of portfolio targets high unmet need diseases
13
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
2
affecting portfolio